Humanigen Publishes on Early Hospital COVID Treatment with Lenzilumab C-Reactiv,e Protein

 

• A sub-analysis of the Phase 3 LIVE-AIR study of lenzilumab showed a strong correlation between C-reactive protein (CRP) and outcomes with lenzilumab treatment with the greatest clinical benefit experienced by patients with baseline CRP<150 mg/L

• In these patients, likelihood of survival without mechanical ventilation (SWOV) was achieved in 90% of LIVE-AIR patients treated with lenzilumab plus standard of care compared to 79% treated with placebo plus standard of care, which was highly statistically significant (HR 2.54, p=0.0009)

• Lenzilumab-treated patients had a 62% relative reduction in the risk of progression to invasive mechanical ventilation or death (OR=0.38; p=0.0053)

https://finance.yahoo.com/news/humanigen-announces-peer-reviewed-publication-120000385.html